Europe
Gilead Sciences and its development partner Galapagos NV announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis.
Advances in data storage and processing, as well as biomarker identification, has led to cutting-edge breakthroughs in clinical and research imaging technology. Here’s a look at just a few of these stories.
After Axovant Sciences’ spectacular clinical trial failure in September 2017, the company has been reorganizing. Today it announced it had completed that reorganization by adding to its executive team and Scientific Advisory Board.
Genmab A/S, and Johnson & Johnson’s Janssen division have pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq.
The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives.
The Memorial Day Holiday is making the U.S. Food and Drug Administration (FDA)’s schedule a bit more complicated. Here’s a look at two more FDA decisions coming up this week.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
One month after Prothena Corporation shuttered its NEOD001 program for AL amyloidosis following a Phase IIb failure, the company initiated a reorganization that includes a workforce reduction of 57 percent.
For some time, the difference between a biotechnology company and a pharmaceutical company was straightforward. A biotechnology focused on developing drugs with a biological basis. Pharmaceutical companies focused on drugs with a chemical basis. But what about nanotechnology? Is that biotechnology?
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
PRESS RELEASES